The Journal of Internal Korean Medicine (대한한방내과학회지)

The Society of Internal Korean Medicine (대한한방내과학회)
권호 표지
DOI QR코드

DOI QR Code

A Case Report of Symptom Improvement with Recurrent Gallbladder Cancer Patients Treated with Korean Medicine-based Integrative Cancer Treatment

한의기반 통합암치료를 통한 재발성 담낭암 환자의 증상 호전 증례보고

  • Ko, Eun-ju (East West Cancer Center, Daejeon Korean Medicine Hospital of Dae-Jeon University) ;
  • Do, Sung-kuk (Dept. of Gastroenterology, School of Korean Medicine, Dae-Jeon University) ;
  • Park, Ji-hye (East west Cancer Center, Seoul Korean Medicine Hospital of Dae-Jeon University) ;
  • Song, Si-yeon (East West Cancer Center, Daejeon Korean Medicine Hospital of Dae-Jeon University) ;
  • Lee, Yeon-weol (East west Cancer Center, Cheonan Korean Medicine Hospital of Dae-Jeon University) ;
  • Yoo, Hwa-seung (East west Cancer Center, Seoul Korean Medicine Hospital of Dae-Jeon University)
  • 고은주 (대전대학교 대전한방병원 동서암센터) ;
  • 도성국 (대전대학교 한의과대학 비계내과학교실) ;
  • 박지혜 (대전대학교 서울한방병원 동서암센터) ;
  • 송시연 (대전대학교 대전한방병원 동서암센터) ;
  • 이연월 (대전대학교 천안한방병원 동서암센터) ;
  • 유화승 (대전대학교 서울한방병원 동서암센터)
  • Received : 2022.05.31
  • Accepted : 2022.07.05
  • Published : 2022.07.05
Download PDF
⟨ Previous Next ⟩

Abstract

Objective: The purpose of this study was to report the improvement effect of symptoms of integrative cancer treatment (ICT) on recurrent gallbladder cancer patients. Methods: A 73-year-old patient with recurrent gallbladder cancer visited the Daejeon Korean Medicine Hospital of Daejeon University East West Cancer Center (EWCC) on February 2022. After the diagnosis of gallbladder cancer, the patient underwent cholecystectomy and relapsed during follow-up. After the operation, the cancer recurred during follow-up, and after radiation treatment, she had been receiving ICT since February 2022. The clinical outcomes were measured by X-ray, computed tomography (CT), laboratory findings, including tumor markers (CEA, CA19-9), and numeric rating scales (NRS). Results: After treatment, abdominal pain was relieved from NRS 5 to 2, and abdominal circumference decreased from 74.5 to 67. During and after treatment, we found neither hepatotoxicity nor nephrotoxicity in the laboratory findings. Conclusion: This case study suggests that ICT may improve symptoms in patients with gallbladder cancer.

Keywords

Acknowledgement

이 연구는 보건복지부 한국보건산업진흥원 한의약선도기술개발사업의 지원에 의하여 이루어진 것임(과제고유번호 : HI19C1046).

References

  1. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist 2010;15(2):168-81. https://doi.org/10.1634/theoncologist.2009-0302
  2. Misra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003;4(3):167-76. https://doi.org/10.1016/S1470-2045(03)01021-0
  3. Bergquist JR, Shah HN, Habermann EB, Hernandez MC, Ivanics T, Kendrick ML, et al. Adjuvant systemic therapy after resection of node positive gallbladder cancer: time for a well-designed trial. Int J Surg 2018;52:171-9. https://doi.org/10.1016/j.ijsu.2018.02.052
  4. Margonis GA, Gani F, Buettner S, Amini N, Sasaki K, Andreatos N, Ethun CG, et al. Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. HPB (Oxford) 2016;18(11):872-8. https://doi.org/10.1016/j.hpb.2016.05.016
  5. Wi Y, Woo H, Won YJ, Jang JY, Shin A. Trends in gallbladder cancer incidence and survival in Korea. Cancer Res Treat 2018;50(4):1444-51. https://doi.org/10.4143/crt.2017.279
  6. Jung KW, Won YJ, Hong S, Kong HJ, Lee ES. Prediction of cancer incidence and mortality in Korea, 2020. Cancer Res Treat 2020;52(2):351-8. https://doi.org/10.4143/crt.2020.203
  7. Kim TG. Patterns of initial failure after resection for gallbladder cancer. implications for adjuvant radiotherapy. Radiat Oncol J 2017;35(4):359-67. https://doi.org/10.3857/roj.2017.00388
  8. Margonis GA, Gani F, Buettner S, Amini N, Sasaki K, Andreatos N, et al. Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US Extra-hepatic Biliary Malignancy Consortium. HPB (Oxford) 2016;18(11):872-8. https://doi.org/10.1016/j.hpb.2016.05.016
  9. Rakic M, Patrlj L, Kopljar M, Klicek R, Kolovrat M, Loncar B, et al. Gallbladder cancer. Hepatobiliary Surg Nutr 2014;3(5):221-6.
  10. Han D, Yang J, Xu F, Huang Q, Bai L, Wei YL, et al. Prognostic factors in patients with gallbladder adenocarcinoma identified using competing-risks analysis: A study of cases in the SEER database. Medicine 2020;99(31):e21322. https://doi.org/10.1097/MD.0000000000021322
  11. Park BK, Yoo HS, Lee YW, Han SS, Cho JH, Son CG, et al. Retrospective cohort analysis for lung cancer patients treated with Wheel Balance Therapy (WBT). Korean J Orient Int Med 2009;19(2):45-56.
  12. Ma Z, Fan Y, Wu Y, Kebebe D, Zhang B, Lu P, et al. Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment. International Journal of Nanomedicine 2019;14:2029-53. https://doi.org/10.2147/IJN.S197889
  13. Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: Cholelithiasis and cancer. Gut Liver 2012;6(2):172-87. https://doi.org/10.5009/gnl.2012.6.2.172
  14. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
  15. Shih SP, Schulick RD, Cameron JL, Lillemoe KD, Pitt HA, Choti MA, et al. Gallbladder cancer: The role of laparoscopy and radical resection. Ann Surg 2007;245(6):893-901. https://doi.org/10.1097/SLA.0b013e31806beec2
  16. Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. Oncologist 2010;15(2):168-81. https://doi.org/10.1634/theoncologist.2009-0302
  17. Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. Hepatobiliary cancers, version 2. J Natl Compr Canc Netw 2014;12(8):1152-82. https://doi.org/10.6004/jnccn.2014.0112
  18. Stein A, Arnold D, Bridgewater J, Goldstein D, Jensen LH, Klumpen HJ, et al. Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. BMC cancer 2015;15:564. https://doi.org/10.1186/s12885-015-1498-0
  19. Wang W, Sun Y, Li X, Li H, Chen Y, Tian Y, et al. Emodin potentiates the anticancer effect of cisplatin on gallbladder cancer cells through the generation of reactive oxygen species and the inhibition of survivin expression. Oncology reports 2011;26(5):1143-8. https://doi.org/10.3892/or.2011.1390
  20. Rho YS, Barrera I, Metrakos P, Kavan P. Complete resolution of metastatic gallbladder cancer after standard Gemcitabine-Cisplatin combination therapy. Cureus 2015;7(12):e415.
  21. Kang HJ, Park JH, Yoo HS, Park YM, Cho CK, Kang IC. Effects of HAD-B1 on the proliferation of A549 cisplatin-resistant lung cancer cells, Molecular Medicine Reports. Mol Med Rep 2018;17(5):6745-51. https://doi.org/10.3892/mmr.2018.8702
  22. Kang HJ, Park SJ, Park YM, Yoo HS, Kang IC. Inhibitory effects of HangAmDan-B1 (HAD-B1) on A549 lung cancer cell proliferation and tumor growth in a xenograft model. Journal of Scientific Research 2016;4(7):187-93.
  23. Park SW, Kim DJ, Kwak MA, Byun JS, Lee JY. The case report about the effect of Injinolyungsangami on the jaundice, Ascites and Edema in Liver Cancer Patient. The journal of Jehan Oriental Medical Academ 2014;2(1):17-26.
  24. Chen Z, Ni W, Yang C, Zhang T, Lu S, Zhao R, et al. Therapeutic effect of Amomum villosum on inflammatory bowel disease in rats. Frontiers in pharmacology 2018;9:639. https://doi.org/10.3389/fphar.2018.00639